Gastric and Esophagogastric Junction AdenocarcinomaPhase 2VESTIGENCT03443856
Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence
A Phase 2 study testing Nivolumab and Ipilimumab and chemotherapy in people with Gastric and Esophagogastric Junction Adenocarcinoma, run by European Organisation for Research and Treatment of Cancer - EORTC at 28 sites in 9 countries.
Trial summary
The primary objective of the trial is to investigate if nivolumab plus ipilimumab given as adjuvant treatment improve disease free survival (DFS) in patients with stage Ib-IVa gastric and esophagogastric junction adenocarcinoma and high risk of recurrence (defined by ypN1-3 and/or R1 status) following neoadjuvant… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Gastric and Esophagogastric Junction Adenocarcinoma
- What is being tested?
- Nivolumab and Ipilimumab and chemotherapy
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 197 participants
- Where
- 28 sitesin 9 countries
- Study dates
- 17 Jul 2019to Jun 2026
- Phase
- Phase 2
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Histologically proven gastric, lower esophageal or GE-junction adenocarcinoma (Siewert I-III)
- Subjects must have completed pre-operative chemotherapy with a fluoropyrimidine-platinum containing regimen and macroscopically complete surgery prior to randomization
- Minimal duration of neoadjuvant chemotherapy should be 6 weeks, maximum 12 weeks.
- Total or distal gastrectomy with D2 lymphadenectomy according to ESMO guidelines should have been completed for gastric and junctional Siewert type III cancers. Ivor Lewis or McKeown oesophagectomy with two field lymphadenectomy should have been performed for junctional Siewert type I cancers. For Siewert type II cancers either total gastrectomy with D2-lymphadenectomy or oesophagectomy with two field lymphadenectomy should have been completed. Open, minimal invasive or hybrid surgical approaches are acceptable as long as the requirements above are fulfilled.
- Regardless of the type of surgery a minimum of 15 lymph nodes should have been resected and examined.
- Recovered from surgery and fit for study treatment as assessed by a multidisciplinary team. Surgery should have been completed 2 to 3 months before randomization.
Show all 26Show fewer
- ypN1-3 status according to current (8th) version of TNM classification system. In case of an ypN0 status patients must meet the inclusion criterion of R1 resection.
- R0 or R1 resection according to current (8th) version of TNM classification system. In case of R0 resection, patients must meet the inclusion criterion of ypN1-3
- WHO performance status score of 0 or 1
- Age ≥ 18 years
- Adequate organ function assessed within 7 days before randomization:
- White blood cell count (WBC) > 2 x 109/L
- Absolute neutrophil count (ANC) > 1.5 x 109/L
- Platelets ≥ 100 x 109/L
- Hemoglobin ≥ 9 g/dL
- Measured/calculated creatinine clearance ≥ 60 mL/min (according to Cockroft-Gault formula).
- Total bilirubin within normal limits (if the patient has documented Gilbert's disease ≤ 1.5 * ULN or direct bilirubin ≤ ULN)
- Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 1.5ULN
- Cardiac assessment by 12 Lead ECG and if clinically indicated, cardiac function assessment (using either echocardiography or MUGA scan)
- All toxicities (exception alopecia) attributed to prior anti-cancer therapy must have resolved to grade 1 (NCI CTCAE version 4) or baseline before administration of study drug.
- Women of childbearing potential (WOCBP*) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin (HCG)) within 24 hours prior to randomization
- Men who are sexually active with an WOCBP must adhere to contraception (condom) during the study and for a period of 7 months after the last dose of the study treatment in the experimental arm and 6 months in the control arm.
- Patients of childbearing / reproductive potential should use highly effective method of birth control measures during the study treatment period and for at least 5 months after the last study treatment. A highly effective method of birth control is defined as those which result in low failure rate (i.e. less than 1% per year) when used consistently and correctly.
- Female subjects who are breast feeding should discontinue nursing prior to the first dose of study treatment and until 6 months after the last study treatment.
- Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
- Before patient registration/randomization, written informed consent must be given according to ICH/GCP, and national/local regulations.
Who cannot join
- R2 resection status
- M1 stage according to current (8th) version of TNM classification system
- Patients who have undergone complete resection of metastases
- Impaired renal, hepatic, cardiac, pulmonary or endocrine status that compromises the eligibility of the patient for postoperative chemotherapy or immunotherapy
- Clinically significant (that is, active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina pectoris, congestive heart failure (New York Heart Association Classification Class ≥ II), or serious cardiac arrhythmia requiring medication
- Subjects with previous malignancies are excluded unless a complete remission or complete resection was achieved at least 5 years prior to study entry. Adequately treated cervical carcinoma in situ, and localized non-melanoma skin cancer are no exclusion criteria, regardless of timepoint of diagnosis.
Show all 19Show fewer
- Subjects with active, known, or suspected infectious or autoimmune disease
- Patients who have received antibiotics within the last 14 days before randomization are excluded.
- Subjects with Type I diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment are permitted to enroll
- Subjects with a condition requiring systemic treatment with either corticosteroids (≥ 10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days of study drug administration
- Subjects with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity
- Subjects with > Grade 1 peripheral neuropathy
- Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
- Prior or concomitant treatment with radiotherapy/radiochemotherapy
- Any positive test result for HBV or HCV indicating acute or chronic infection
- Known history of HIV or known AIDS and, if required by local practice or positive HIV testing at screening
- Known uncontrollable hypersensitivity to the components of cisplatin/oxaliplatin, fluorouracil (5-FU) or capecitabine, epirubicine or docetaxel
- Known dihydropyrimidine dehydrogenase (DPD) deficiency
- Ongoing or concomitant use of the antiviral drug sorivudine or its chemically related analogs, such as brivudine.
Trial locations and contacts
28 sites in 9 countries.
28 sites in 9 countries
Germany8 sites
Charite - Universitaetsmedizin Berlin
Berlin
Kliniken Essen-Mitte
Essen
Universitaetsklinikum Freiburg
Freiburg im Breisgau
Universitaets Krankenhaus Eppendorf - Universitaetsklinikum Hamburg-Eppendorf KE - University Cancer Center
Hamburg
SLK-Kliniken Heilbronn
Heilbronn
Universitaetsklinikum Leipzig-Ambulanzen/Sprechstunden
Leipzig
Klinikum Rechts der isar Der Technische Universitaet Muenchen - Klinikum Rechts Der Isar
München
Universitaetsklinikum Tuebingen-Uni Kliniken Berg
Tübingen
Spain4 sites
Institut Catalan d'Oncologia - ICO Badalona
Badalona
Hospital Universitario 12 de Octubre
Madrid
Complejo Hospitalario A
Pamplona
Hospital Clinico Universitario de Valencia
Valencia
United Kingdom4 sites
Cambridge University Hospital NHS
Cambridge
Royal Marsden Hospital
London
University College London Hospitals NHS Foundation Trust
London
Royal Marsden Hospital
Sutton
France3 sites
CHRU de Lille - Hopital Huriez
Lille
Hôpital Privé Jean Mermoz
Lyon
Gustave Roussy
Villejuif
Italy3 sites
Azienda Ospedaliera a Papa Giovanni XXIII
Bergamo
Istituto Europeo di Oncologia
Milan
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Naples
Czechia2 sites
Masaryk Memorial Cancer Institute
Brno
University Hospital Hradec Kralove
Hradec Králové
Israel2 sites
Rambam Health Care Campus, Oncology Institute
Haifa
Rabbin Medical Centre - Tel Aviv
Tel Aviv
About this study
Official title: Adjuvant Immunotherapy in Patients With Resected Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): an Open Label Randomized Controlled Phase-2-study
The primary objective of the trial is to investigate if nivolumab plus ipilimumab given as adjuvant treatment improve disease free survival (DFS) in patients with stage Ib-IVa gastric and esophagogastric junction adenocarcinoma and high risk of recurrence (defined by ypN1-3 and/or R1 status) following neoadjuvant chemotherapy and resection.
Other study objectives:
- To investigate the safety and effect of adjuvant immunotherapy on long term oncologic outcomes and quality of life of patients in the study
- To correlate nutritional status assessment on outcomes and quality of life of patients
- Being tested
- Nivolumab and Ipilimumab, chemotherapy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nivolumab and IpilimumabDrug
Nivolumab 1 mg/kg IV Q3W plus Ipilimumab 3 mg/kg IV Q3W for 4 cycles (3 months) followed by nivolumab 240 mg flat-dose IV Q2W for 9 months.Total treatment time 1 year
chemotherapyOther
Completion of the perioperative treatment according to the 2016 ESMO guidelines (change of regimen is not allowed).
| Study group | Role | What they receive |
|---|---|---|
| chemotherapy arm | Other | Completion of the perioperative treatment according to the 2016 ESMO guidelines (change of regimen is not allowed). Receives: Other: chemotherapy |
| immunotherapy arm | Experimental | Treatment: Nivolumab 1 mg/kg IV Q3W plus Ipilimumab 3 mg/kg IV Q3W for 4 cycles (3 months) followed by nivolumab 240 mg flat-dose IV Q2W for 9 months.Total treatment time 1 year. No chemotherapy. Receives: Drug: Nivolumab and Ipilimumab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Disease free survival (DFS)
Disease free survival is defined as the time interval between randomization and the date of disease recurrence or death from any cause, whichever comes first. Patients alive with no disease recurrence are censored at the date of the last follow-up examination. randomization and the date of disease recurrence or death from any cause, whichever comes first.
Measured: 22 months after last patient in
Secondary outcomes (5)
Overall survival (OS)
Overall survival is defined as the time interval between the date of randomization and the date of death from any cause. Patients who are still alive when last traced are censored at the date of last follow up.
Measured: 5 years after last patient in
Loco-regional failure rates
Local recurrence is defined as evidence of tumor in the anastomotic area. Regional recurrence is defined as evidence of tumor in the locoregional lymph nodes or other surrounding structures apart from the anastomotic site. Death in absence of loco-regional failure will be considered as a competing risk in the estimation of the cumulative incidence of loco-regional failures. Patients who have not had any such event at the time of data analysis will be censored at the date of the last follow-up examination.
Measured: 5 years after last patient in
Distant failure rates
The diagnosis of distant recurrence requires imaging confirmed by pathology. Once recurrence is confirmed, the date of recurrence is the first date when recurrence was suspected.
Distant recurrence is defined as recurrence not considered as local or regional.Death in absence of distant failure will be considered as a competing risk in the estimation of the cumulative incidence of distant failures. Patients who have not had any such event at the time of data analysis will be censored at the date of the last follow-up examination
Measured: 5 years after last patient in
Rate of adverse events according to NCI-CTCAE
All adverse events will be recorded; the investigator will assess whether those events are drug related (reasonable possibility, no reasonable possibility) and this assessment will be recorded in the database for all adverse events. AEs will be collected at baseline from randomization.
Only the worst grade per CTCAE category will be recorded per cycle. All adverse events must be followed until resolution or stabilization. Adverse Events of Special Interest for ipilimumab and nivolumab requiring a close follow-up were identified as a result of signals observed from previous studies involving the protocol treatments. These events require a close follow-up
Measured: 5 years after last patient in
Quality of life assessed with the EORTC Quality of Life Questionnaire (QLQ-C30) version 3
Quality of life will be assessed with the EORTC Quality of Life Questionnaire (QLQ-C30) version 3. These include five functional scales (physical, role, emotional, social, and cognitive), three symptom (fatigue, nausea and vomiting and pain) and a global health status/QoL scale and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties). The primary HRQoL endpoints that are considered relevant for this study are global health status/QoL and physical functioning.A difference of 10 points on the 100-point QLQ-C30 scale between the two arms will be considered as clinically relevant
Measured: questionnaires will be completed at baseline, week 6, 3 months, 6 months, 9 months, 12 months, 15 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Feb 2018
- Study start17 Jul 2019
- Primary completion12 Dec 2023
- Study completionJun 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Gastric and Esophagogastric Junction AdenocarcinomaStudies of the same condition, open and under way.
- More trials run by European Organisation for Research and Treatment of Cancer - EORTCThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 197 participants (actual)
Sponsor and investigators
- Sponsor type
- Research network
- Responsible party
- Sponsor
- Investigators
- Florian Lordick, Study chair, Universitaetsklinikum Leipzig-Ambulanzen/Sprechstunden, Leipzig, GermanyMaren Knoedler, Study chair, Universitaetsklinikum Leipzig-Ambulanzen/Sprechstunden, Leipzig, GermanyElizabeth Smyth, Study chair, Cambridge University Hospital NHS - Cambridge, UK
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03443856
- Sponsor's protocol ID
- EORTC 1707-GITCG
- Other IDs
- 2018-000406-36, 2018
- Acronym
- VESTIGE
- Status last verified
- Jan 2024
- First submitted
- 19 Feb 2018
- Last updated
- 5 Jan 2024
- Results posted
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Smyth E, Knodler M, Giraut A, Mauer M, Nilsson M, Van Grieken N, Wagner AD, Moehler M, Lordick F. VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study. Front Oncol. 2020 Jan 30;9:1320. doi: 10.3389/fonc.2019.01320. eCollection 2019.
PubMed 32083013